Gonorrhoea in 21st century--international and Polish situation
- PMID: 25004630
Gonorrhoea in 21st century--international and Polish situation
Erratum in
- Przegl Epidemiol. 2014;68(2):322
Abstract
Gonorrhoea, according to the latest World Health Organization (WHO) estimates in 2008, is the most frequent bacterial sexually transmitted infection globally, accounting for 106.1 million new cases among adults. Of those cases, 3.4 (3.2%) million were in the WHO European Region. In the European Union and European Economic Area, the incidence of reported cases was 12.6 per 100,000 inhabitants in 2011. The highest incidences were noted in the United Kingdom (37.1), Latvia (24.4) and Ireland (18.6). However, in Poland from 2000 to 2011 the reported incidence declined and was only 0.8-0.9 per 100,000 inhabitants in 2011, that might indicate a suboptimal diagnostics and incomplete case reporting and epidemiological surveillance. A study surveying the diagnostics for gonorrhoea and the case reporting system, including the local and national epidemiological surveillance, in Poland is recommended. The high resistance in Neisseria gonorrhoeae to nearly all antimicrobials introduced for treatment of gonorrhoea is an exceedingly serious problem globally. A few years ago the first extensively-drug resistant N. gonorrhoeae strains with high-level resistance to ceftriaxone, the last remaining option for first-line empirical monotherapy, were reported. Due to this emergent situation, in 2012 the WHO and the European Centre for Disease Prevention and Control (ECDC) launched a global action plan and regional response plan, respectively, to combat the spread of multidrug resistant N. gonorrhoeae. Additionally, an updated European guideline on the diagnosis and treatment of gonorrhoea, recommending treatment with ceftriaxone together with azithromycin, was published in 2012. Worryingly, no antimicrobial susceptibility data for N. gonorrhoeae strains circulating in Poland have been internationally reported in several decades. It is imperative to implement some regular and quality assured antimicrobial susceptibility surveillance for N. gonorrhoeae in Poland and the official Polish treatment guidelines (from 1970s) recommending penicillin G as first-line treatment for gonorrhoea need to be promptly revised.
Similar articles
-
Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015.BMC Infect Dis. 2017 Sep 11;17(1):617. doi: 10.1186/s12879-017-2707-z. BMC Infect Dis. 2017. PMID: 28893203 Free PMC article.
-
Gonorrhoea and gonococcal antimicrobial resistance surveillance networks in the WHO European Region, including the independent countries of the former Soviet Union.Sex Transm Infect. 2013 Dec;89 Suppl 4:iv42-6. doi: 10.1136/sextrans-2012-050909. Sex Transm Infect. 2013. PMID: 24243879 Review.
-
Background review for the '2020 European guideline for the diagnosis and treatment of gonorrhoea in adults'.Int J STD AIDS. 2021 Feb;32(2):108-126. doi: 10.1177/0956462420948739. Epub 2020 Dec 15. Int J STD AIDS. 2021. PMID: 33323071 Review.
-
Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and treatment of gonorrhoea patients in Ternopil and Dnipropetrovsk regions of Ukraine, 2013-2018.APMIS. 2019 Jul;127(7):503-509. doi: 10.1111/apm.12948. Epub 2019 May 21. APMIS. 2019. PMID: 30903707
-
Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of Neisseria gonorrhoeae.J Antimicrob Chemother. 2014 Aug;69(8):2086-90. doi: 10.1093/jac/dku118. Epub 2014 Apr 28. J Antimicrob Chemother. 2014. PMID: 24777907
Cited by
-
A Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infection.Sex Transm Dis. 2018 Feb;45(2):87-91. doi: 10.1097/OLQ.0000000000000698. Sex Transm Dis. 2018. PMID: 29329176 Free PMC article.
-
Analysis of the sex ratio of reported gonorrhoea incidence in Shenzhen, China.BMJ Open. 2016 Mar 14;6(3):e009629. doi: 10.1136/bmjopen-2015-009629. BMJ Open. 2016. PMID: 26975933 Free PMC article.